Content area
Full Text
Drug maker Alexion said Tuesday it will reduce its global workforce by 20% and move its headquarters as it seeks to rebuild a drug pipeline that is heavily dependent on the blood disorder treatment Soliris.
The moves continue Alexion’s “strategic assessment” of its organization amid pressure to cut costs and federal investigations of its sales practices. Longtime CEO David Hallal left the company in January and CFO Paul Clancy is the third executive to hold that position since December.
The layoffs announced Tuesday follow a 7% workforce...